@entity4236 : the long-term outcome and late XXXX of multimodal therapy including radiotherapy based on treatment planning using computed tomography.

@entity5 @entity4236 @entity1 @entity137
BACKGROUND: @entity4236 ( @entity4236 ) is a rare @entity5 originating from olfactory epithelium. Here we retrospectively analyzed the long-term treatment outcomes and @entity137 of radiotherapy for @entity4236 @entity1 for whom computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of radiotherapy in the light of recent advanced technology and chemotherapy. METHODS: Seventeen @entity1 with @entity4236 treated between July 1992 and June 2013 were included. Three @entity1 were Kadish stage B and 14 were stage C. All @entity1 were treated with radiotherapy with or without surgery or chemotherapy. The radiation dose was distributed from 50 Gy to 66 Gy except for one @entity1 who received 40 Gy preoperatively. RESULTS: The median follow-up time was 95 months (range 8-173 months). The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively. Five @entity1 with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months). Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three @entity1 . CONCLUSION: Multimodal therapy including radiotherapy with precise treatment planning based on CT simulation achieved an excellent local control rate with acceptable @entity137 and reasonable overall survival for @entity1 with @entity4236 .
